
Following Ascendis Pharma’s (NASDAQ:ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the likelihood of success of its TCP has increased from 60% to 75%, according to BofA Securities.
The Ascendis Pharma Analyst: Tazeen Ahmad upgraded the rating for Ascendis Pharma from Neutral to Buy, while raising the price target from $148 to $161.